By Marie Rosenthal, MS
The FDA granted a new indication for Pfizer’s respiratory syncytial virus prefusion F (RSVpreF) vaccine (Abrysvo) to prevent lower respiratory tract disease (LRTD) in younger adults whose chronic condition could put them at risk for disease.
The vaccine is now indicated for people with certain chronic conditions who are 18 through 59 years of age. These conditions include cardiovascular disease, diabetes, obesity, asthma, chronic obstructive pulmonary disease, liver